Welcome to our dedicated page for HUMANA SEC filings (Ticker: HUM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HUMANA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HUMANA's regulatory disclosures and financial reporting.
Mehta Japan reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc.’s Chief Information Officer Japan Mehta received a grant of 9,448 shares of Humana common stock, awarded at no cash cost as equity compensation. Following this award, Mehta directly holds 17,176 shares, including 15,200 restricted stock units that each represent a contingent right to one Humana share under the company’s 2019 Amended & Restated and 2026 Stock Incentive Plans, exempt under Rule 16b-3.
Humana Inc. President, Enterprise Growth, David Dintenfass reported a grant of 11,273 shares of Humana common stock at a price of $0.00 per share, raising his direct holdings to 25,407 shares.
He also holds options on 51,389 shares of Humana common stock with an exercise price of $367.21 per share, expiring on February 21, 2031, granted under Humana’s stock incentive plan and vesting in three annual increments from February 21, 2025 to February 21, 2027. His position includes 18,617 restricted stock units, each representing a contingent right to receive one share of Humana common stock.
Rechtin James A. reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. President & CEO James A. Rechtin reported an award of 35,633 shares of Humana common stock, held indirectly through two revocable trusts for the benefit of him and his spouse. After this grant, these trusts hold 63,938 shares of Humana common stock.
Rechtin also holds equity awards under Humana’s stock incentive plans, including 2,183 restricted stock units, each representing one future share of Humana common, and stock options covering 15,772 shares at $367.21 per share and 29,230 shares at $458.185 per share, generally vesting in three annual increments from 2025 to 2027 and expiring in 2031.
O'Hara Michelle A. reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. reported that Chief Human Resources Officer Michelle A. O'Hara received a grant of 10,485 shares of Humana common stock as a stock award. Following this grant, she directly holds 20,026 shares of common stock, including 17,997 restricted stock units that each represent a contingent right to receive one Humana common share under the company’s 2019 Amended & Restated and 2026 Stock Incentive Plans.
Field Robert Stuart reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. director Robert Stuart Field received a grant of 852 restricted stock units (RSUs) of Humana common stock. The award represents an initial grant of $200,000 in RSUs under the company’s annual Director Compensation Program and 2026 Stock Incentive Plan.
Each RSU carries a right to receive one share of Humana common stock and is reported as exempt under Rule 16b-3(d)(1) & (3). The entire award will be forfeited if his board service is less than one year. Following this grant, he directly holds 852 RSUs.
Humana Inc. Chief Legal Officer Joseph C. Ventura received 10,318 shares of Humana Common stock as a grant on May 1, 2026, at $0.00 per share, bringing his direct holdings to 27,405 shares.
He also holds 294 Humana Common shares indirectly through a retirement savings plan. In addition, he retains several option awards on Humana Common stock with exercise prices between $350.7875 and $510.2425 per share, expiring from 2027 through 2031.
Shetty Sanjay K reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. President, CenterWell Sanjay K. Shetty received a grant of 9,945 shares of Humana Common stock as compensation. The shares were awarded at a price of $0.0000 per share and increase his directly held common stock position to 22,088 shares.
The filing also shows he holds stock options giving the right to buy 6,572 Humana shares at $367.21 per share expiring on February 21, 2031, and 3,964 shares at $487.1602 per share expiring on April 1, 2030. His reported holdings include 18,763 restricted stock units that can settle into Humana common shares.
Humana Inc. executive Aaron Martin received a grant of 8,206 shares of Humana common stock as a compensation award. The award was recorded at a price of $0.0000 per share and classified as a grant or other acquisition rather than an open-market purchase.
Following this transaction, Martin directly holds 25,237 restricted stock units, each representing a contingent right to receive one share of Humana Inc. common stock. These units were granted under the company’s 2019 Amended & Restated and 2026 Stock Incentive Plans and are exempt under Rule 16b-3.
Vanguard Capital Management reports beneficial ownership of 9,068,300 shares of Humana Inc Common Stock, representing 7.55% of the class as of 03/31/2026. The filer discloses sole voting power of 1,229,538 shares and sole dispositive power over 9,068,300 shares. The filing states these holdings include shares held for Vanguard funds and managed accounts and attributes voting/dispositive arrangements to Vanguard affiliates.